Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
34results about How to "Delay slowing" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Recombinant adenoviruses and use thereof
ActiveUS20150291935A1Diminishment of extentAvoid spreadingAntibacterial agentsAntimycoticsSimian AdenovirusesDisease
The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
Owner:WASHINGTON UNIV IN SAINT LOUIS +1
3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
InactiveUS20090131503A1Diminishment of extentAvoid spreadingBiocideNervous disorderNorepinephrine transporterAdrenergic
The present invention relates to novel 3,5-substituted indole compounds of Formula (I) having nitric oxide synthase (NOS) inhibitory activity together with inhibitory activity at the norepinephrine transporter (NET), to pharmaceutical and diagnostic compositions containing them, and to their medical use.
Owner:NEURAXON INC
Peptides derived from human pcsk9 catalytic domain and uses thereof for promoting ldl-r activity
ActiveUS20180023071A1Reduce severityDiminishment of extentPeptide/protein ingredientsMetabolism disorderCholesterol bloodPCSK9
Owner:AQUR BIOSCIENCES INC
Residualizing linkers and uses thereof
ActiveUS20160279272A1Diminishment of extentAvoid spreadingRadioactive preparation carriersPharmaceutical active ingredientsCombinatorial chemistry
The present invention relates to conjugates including a residualizing linker, methods for their production, and uses thereof.
Owner:CENT FOR PROBE DEV & COMMLIZATION
Indole compounds and methods for treating visceral pain
InactiveUS20090192157A1Effect be exertDiminishment of extentBiocideNervous disorderMammalVisceral pain
The invention features methods of treating visceral pain or a condition in a mammal caused by the action of nitric oxide synthase (NOS) or by the action of serotonin 5HT1D / 1B receptors, by administering to a patient in need thereof a therapeutically effective amount of an indole compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof. The methods of the invention may further comprise the administration of additional therapeutic agent. The invention also features new compounds of Formula (I), pharmaceutical compositions thereof, and methods of resolving enantiomeric mixtures.
Owner:NEURAXON INC
Compositions comprising a prostaglandin for treating neuropsychiatric conditions
ActiveUS20130309330A1Diminishment of extentAvoid spreadingBiocideNervous disorderLatanoprostBipolar mood disorder
The present invention relates to methods and compositions for the treatment of neuropsychiatric conditions (e.g., bipolar disorder) by administration of prostaglandin or prostaglandin derivatives (e.g., latanoprost) to a subject (e.g., a human).
Owner:NEUROTHERYX CANADA LTD
Method of enhancing hair growth
InactiveUS20120302588A1Shorten the timeIncrease ratingsOrganic active ingredientsBiocideHair growthHair streams
Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include bimatoprost and minoxidil in a vehicle for topical application to the skin of a mammal, e.g. a human, whereby the combination of bimatoprost and minoxidil produces a faster onset of hair growth in humans or other mammals and wherein said composition brings about a synergestic result of faster onset of hair growth as compared to compositions comprising bimatoprost and minoxidil, alone.
Owner:ALLERGAN INC
Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
InactiveUS7824687B2Delay slowingDelay disease progressionBiocideOrganic chemistry methodsCancer preventionSynthesis methods
The present invention provides novel clustered multi-antigenic constructs having the structure:and methods for the synthesis thereof. In still another aspect, the present invention provides methods for the treatment of cancer, preferably for the prevention of recurrence of cancer, and methods for inducing antibodies in a subject, comprising administering to a subject in need, an effective amount of any of the inventive constructs as disclosed herein, either in conjugated form or unconjugated and in combination with a suitable immunogenic carrier.
Owner:SLOAN KETTERING INST FOR CANCER RES
Methods for treating diseases related to the wnt pathway
ActiveUS10624949B1Relieve symptomsDiminishment of extentPeptide/protein ingredientsMicrobiological testing/measurementGenomeDisease status
The present invention relates to methods for treating a disease, in which the disease arises from dysregulation of the Wnt signaling pathway. In some instances, the disease can be treated by administering a Wnt pathway inhibitory compound. In other instances, the method optionally includes conducting a genome-wide screening to determine one or more genes resulting in a reduced disease state and then identifying the gene(s) as being involved in the Wnt signaling pathway.
Owner:NAT TECH & ENG SOLUTIONS OF SANDIA LLC
Methods for the treatment of cysteamine sensitive disorders
ActiveUS20200268692A1Extension of timeReduce in quantityPowder deliveryNervous disorderCysteamineDisease
The invention features methods for the treatment of cystinosis and other cysteamine sensitive disorders in a subject including administration of a disulfide convertible to cysteamine in vivo. The methods can include the separate administration of a reducing agent to the subject to increase the bioavailablity and extend the plasma pharmacokinetic profile of the cysteamine produced following administration of the disulfide. The methods permit sustained cysteamine plasma concentrations in a subject.
Owner:THIOGENESIS THERAPEUTICS INC
Methods and pharmaceutical compositions for the treatment of cardiomyopathies
InactiveUS20190350955A1Improve heart functionReduces eccentric remodelingOrganic active ingredientsPharmaceutical delivery mechanismNicotinamide riboside kinaseNicotinamide riboside
The present invention relates to methods and pharmaceutical compositions for the treatment of cardiomyopathies. The inventors showed that the nicotinamide riboside kinase Nmrk2 gene involved in NAD+ biosynthetic pathway is strongly induced in the heart of the mouse models of dilated cardiomyopathy and that Nmrk2 is an AMPK and PPARα responsive gene. They also showed that the NMRK enzymes substrate nicotinamide riboside supplementation in food markedly improves cardiac functions and reduces eccentric remodeling. The inventors demonstrated that both the NMRK1 and NMRK2 protein are expressed in the human healthy heart, that NMRK2 protein level is increased in human failing hearts as it is the case in mouse failing hearts in several models of heart failure and cardiomyopathies. In particular, the present invention relates to nicotinamide riboside for use in the treatment of cardiomyopathy in a human subject in need thereof.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3
Tunable metal-organic framework compositions and methods thereof
ActiveUS11007516B1Relieve symptomsDiminishment of extentPowder deliveryOrganic-compounds/hydrides/coordination-complexes catalystsPhysical chemistryMetal-organic framework
Owner:NAT TECH & ENG SOLUTIONS OF SANDIA LLC
Degradation of chemical agents using metal-organic framework compositions
ActiveUS11077327B1Relieve symptomsReduce frequencyOrganic-compounds/hydrides/coordination-complexes catalystsMetal-organic frameworkOrganic chemistry
The present invention relates to a metal-organic framework composition, as well as constructs and methods thereof. In one particular example, the composition is employed to degrade a chemical agent in a non-aqueous environment.
Owner:NAT TECH & ENG SOLUTIONS OF SANDIA LLC
Methods and compositions for malic enzyme 2 (ME2) as a target for cancer therapy
ActiveUS9539323B2Lower Level RequirementsDiminishment of extentHeavy metal active ingredientsCompound screeningDiseaseAnticarcinogen
The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing cancer and other related diseases that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include combination therapy, such as with a combination of two or more ME2 inhibitors or a combination of an ME2 inhibitor and an anticancer agent.
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC
Devices, kits, and methods for determining ineffectiveness of anesthetics
InactiveUS20180243448A1ConfidenceDiminishment of extentCompounds screening/testingNervous disorderMedicineLidocaine
In general, the invention provides kits, devices, and methods for determining the ineffectiveness of an anesthetic, (e.g., lidocaine), using a topical approach that avoids injection. The methods typically employ the placement of aliquots of two different formulations, at least one including an anesthetic, in different locations on a subject. Further embodiments may employ a single formulation including the anesthetic.
Owner:ALKALIDX INC
Site-specific modification of proteins through chemical modification enabling protein conjugates, protein dimer formation, and stapled peptides
ActiveUS8927485B2Diminishment of extentAvoid spreadingPeptide/protein ingredientsDepsipeptidesDiseaseDimer
Owner:ADVANCED PROTEOME THERAPEUTICS
Site-specific labeling and targeted delivery of proteins for the treatment of cancer
ActiveUS9545449B2Diminishment of extentAvoid spreadingPeptide/protein ingredientsPharmaceutical non-active ingredientsCancer cellPharmacophore
The present invention relates to the formation of protein conjugates from proteins chemically modified for linkage to (1) anticancer drug pharmacophores, (2) ligands to biomarkers on cancer cell surfaces, (3) and / or another protein molecule. It provides and specifies new compositions, methods and combinations for tumor, and tumor vasculature targeting and cancer treatment.
Owner:ADVANCED PROTEOME THERAPEUTICS
Method of enhancing hair growth
InactiveUS8932567B2Shorten the timeIncrease ratingsCosmetic preparationsBiocideHair streamsHair growth
Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include bimatoprost and minoxidil in a vehicle for topical application to the skin of a mammal, e.g. a human, whereby the combination of bimatoprost and minoxidil produces a faster onset of hair growth in humans or other mammals and wherein said composition brings about a synergestic result of faster onset of hair growth as compared to compositions comprising bimatoprost and minoxidil, alone.
Owner:ALLERGAN INC
Aav1 vectors and uses thereof for treatment of otic indications
PendingUS20210355504A1Strong expressionSuperior tropismSenses disorderPharmaceutical delivery mechanismVestibular dysfunctionElectrophonic hearing
The invention provides AAV1 vectors that can be used to transduce multiple inner ear cell types and their use for treatment of hearing loss, deafness, tinnitus, and vestibular dysfunction.
Owner:DECIBEL THERAPEUTICS INC
Amine cationic lipids and uses thereof
ActiveUS9549983B2Diminishment of extentAvoid spreadingOrganic active ingredientsPowder deliveryLipid formationIn vivo
The present invention relates to lipid compounds and uses thereof. In particular, the compounds include a class of cationic lipids having an amine moiety, such as an amino-amine or an amino-amide moiety. The lipid compounds are useful for in vivo or in vitro delivery of one or more agents (e.g., a polyanionic payload or an antisense payload, such as an RNAi agent).
Owner:DICERNA PHARM INC
Indole compounds and methods for treating visceral pain
Owner:NEURAXON INC
Cochlear outer hair cell promoters and uses thereof
PendingUS20220288236A1Improve survivalReduce developmentSenses disorderVectorsHL - Hearing lossTherapeutic protein
The disclosure provides polynucleotides containing outer hair cell-specific promoters, as well as vectors containing the same, that can be used to promote expression of a transgene specifically in outer hair cells. The polynucleotides described herein may be operably linked to a transgene, such as a transgene encoding a therapeutic protein, so as to promote outer hair cell-specific expression of the transgene. The polynucleotides described herein may be operably linked to a therapeutic transgene and used for the treatment of subjects having or at risk of developing hearing loss.
Owner:DECIBEL THERAPEUTICS INC
Methods and Pharmaceutical Compositions (NTSR1 Inhibitors) for the Treatment of Hepatocellular Carcinomas
InactiveUS20180134788A1Preventing and delaying recurrenceDelay slowingImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsHepatocellular carcinomaBiological activation
The present disclosure relates to methods and pharmaceutical compositions for the treatment of hepatocellular carcinomas (HCC in abbreviation, the term “hepatocellular carcinoma” has its general meaning in the art and refers to the cancer developed in hepatocytes see page 2 lines 24-30 of the present application) comprising administering to the subject a therapeutically effective amount of an inhibitor of NTSR1 (Neurotensin Receptor 1) activation or expression. The examples show the expression of NTSR1 in HCC cell lines and the role of the NTS / NTSR1 complex in these cell lines, thereby showing the role of the complex in tumour progression.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +1
Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
ActiveUS10954299B2Reduce the burden onReduce infiltrationAntibacterial agentsImmunoglobulins against cytokines/lymphokines/interferonsLung alveolusAntibiotic resistance
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3
Cochlear inner hair cell promoters and uses thereof
PendingUS20220348965A1Improve survivalReduce developmentSenses disorderGenetic material ingredientsHL - Hearing lossCochlear Inner Hair Cells
The disclosure provides polynucleotides containing inner hair cell-specific promoters, as well as vectors containing the same, that can be used to promote expression of a transgene specifically in inner hair cells. The polynucleotides described herein may be operably linked to a transgene, such as a transgene encoding a therapeutic protein, so as to promote inner hair cell-specific expression of the transgene. The polynucleotides described herein may be operably linked to a therapeutic transgene and used for the treatment of subjects having or at risk of developing hearing loss.
Owner:DECIBEL THERAPEUTICS INC
Methods for diagnosing high-risk cancer using polysialic acid and one or more tissue-specific biomarkers
Described herein are methods for diagnosing high-risk cancer in a subject by detecting PolySialic Acid (polySia) in a biological sample obtained from the subject, or by detecting polySia and one or more tissue-specific markers in a biological sample obtained from the subject.
Owner:GLYCA INC
Expanded pore particles and delivery methods thereof
ActiveUS10933027B1Relieve symptomsDiminishment of extentNanotechSpecial deliveryPolymer sciencePolymer chemistry
The present invention relates to a construct including a porous core, a cargo, and a spacer disposed between the core and the cargo. In some examples, the construct further includes an outer layer composed of a lipid, a polymer, or a combination thereof. Methods of making and employing such constructs are also described herein.
Owner:NAT TECH & ENG SOLUTIONS OF SANDIA LLC
Methods and pharmaceutical compositions for the treatment of pulmonary bacterial inffections
ActiveUS20190144539A1Reduce the burden onReduce infiltrationAntibacterial agentsImmunoglobulins against cytokines/lymphokines/interferonsAlveolar lavage fluidAntibiotic resistance
The present invention relates to methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections. The increasing burden of antimicrobial resistance coupled with the decreasing number of antibiotics in development has urged for strategies to elaborate new therapies. The inventors showed a therapeutic effect of IL-20 receptor 10 antagonists in pulmonary bacterial infection mouse model. Indeed, they demonstrated that treatment with IL-20 receptor antagonists reduces bacterial burden, cellular infiltration and inflammation in bronchoalveolar lavage fluid (BALF) and lung. In particular, the present invention relates to an antagonist of IL-20 cytokines, or / and an antagonist of IL-20RB receptor for use in a method for the treatment of pulmonary bacterial infections in a subject in 15 need thereof.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3
Methods for diagnosing high-risk cancer using polysialic acid and one or more tissue-specific biomarkers
Described herein are methods for diagnosing high-risk cancer in a subject by detecting PolySialic Acid (polySia) in a biological sample obtained from the subject, or by detecting polySia and one or more tissue-specific markers in a biological sample obtained from the subject.
Owner:GLYCA INC
Conformation-specific antibodies that bind nuclear factor kappa-light-chain-enhancer of activated b cells
PendingUS20220348645A1Diminishment of extentDelay slowingAntibacterial agentsImmunoglobulins against animals/humansAntigen Binding FragmentActivation cells
Described are conformation-specific antibodies or antigen-binding fragments that specifically bind to the trans conformation of phosphorylated-Threonine254-Proline (pThr254-Pro) of the p65 subunit of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). Also described are related pharmaceutical compositions, polynucleotides, peptides, vectors, host cells, methods of production, methods of treatment, diagnostic methods, and kits.
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com